Clinical Research Directory

Inclusion Criteria: All patients who, according to the recommendations for use, can receive LA- injectable Cabotegravir +Rilpivirine therapy will be invited to participate in the study. Recommendations for use: * HIV-1 positive patients, on antiretroviral therapy * Older than 18 years of age at the time of signing the informed consent * Undetectable HIV viral load in the last 6 months * Willing to switch from oral to injectable therapy Exclusion Criteria: These criteria are defined for those patients who, according to the recommendations for use, cannot receive the therapy: * Previous virological failure * Any evidence of primary resistance or the presence of any major known INI or NNRTI resistance-associated mutation by any historical resistance test result. * Patients with decompensated pathology (physical or mental) or active opportunistic infection at the time of admission * Concomitant use with: rifampin, carbamazepine, oxcarbazepine, phenytoin and phenobarbital or any contraindication to one of the drugs of the study * Known hepatitis B co-infection * Pregnancy (There is insufficient data for people who become pregnant on CAB or those planning to conceive because available pregnancy PK data are limited (n = 3), and data on clinical outcomes in pregnancy are extremely limited. Therefore, CAB is Not Recommended for pregnant or nonpregnant people initiating or restarting ART or for those whose current regimen is not well tolerated and/or not fully suppressive)